BTIG analyst Thomas Shrader lowered the firm’s price target on Stoke Therapeutics (STOK) to $28 from $29 and keeps a Buy rating on the shares. The company’s 36-month data for Zorevunersen seems to bury any remaining question, demonstrating seizure reductions deepening in the third year of treatment for patients that started at sub-optimal loading doses and starting and staying impressive for patients that started on the 45 mg loading doses, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke Therapeutics: Promising Outlook with Strong Financial Position and Advancing Clinical Trials Justifies Buy Rating
- Promising Developments in Stoke Therapeutics’ Clinical Trials Support Buy Rating
- Positive Outlook for Stoke Therapeutics: Promising Clinical Data and Strong Financial Position
- Stoke Therapeutics Advances RNA Medicine with Strong Q2 Results
- Stoke Therapeutics reports Q2 EPS (40c), consensus (54c)